

Datasheet for ABIN1882233  
**anti-CYP2C9 antibody (N-Term)**[Go to Product page](#)

1 Image

3 Publications

## Overview

Quantity:	0.1 mL
Target:	CYP2C9
Binding Specificity:	AA 82-110, N-Term
Reactivity:	Human
Host:	Mouse
Clonality:	Monoclonal
Conjugate:	This CYP2C9 antibody is un-conjugated
Application:	Western Blotting (WB)

## Product Details

Immunogen:	This CYP2C9 antibody is generated from mice immunized with a KLH conjugated synthetic peptide between 82-110 amino acids from the N-terminal region of human CYP2C9.
Clone:	682CT5-6-2
Isotype:	IgM
Purification:	Mouse monoclonal antibody supplied in crude ascites with 0.09% (W/V) sodium azide.

## Target Details

Target:	CYP2C9
Alternative Name:	CYP2C9 ( <a href="#">CYP2C9 Products</a> )
Background:	This gene encodes a member of the cytochrome P450 superfamily of enzymes. The

## Target Details

cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by rifampin. The enzyme is known to metabolize many xenobiotics, including phenytoin, tolbutamide, ibuprofen and S-warfarin. Studies identifying individuals who are poor metabolizers of phenytoin and tolbutamide suggest that this gene is polymorphic. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24.

Molecular Weight: 55628

NCBI Accession: [NP\\_000762](#)

UniProt: [P11712](#)

## Application Details

Application Notes: WB: 1:100~1600

Restrictions: For Research Use only

## Handling

Format: Liquid

Buffer: Mouse monoclonal antibody supplied in crude ascites with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide


Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C, -20 °C

Expiry Date: 6 months

## Publications

Product cited in: Mishra, Chandravanshi, Trigun, Krishnamurthy: "Ambroxol modulates 6-Hydroxydopamine-induced temporal reduction in Glucocerebrosidase (GCase) enzymatic activity and Parkinson's disease symptoms." in: **Biochemical pharmacology**, Vol. 155, pp. 479-493, (2019) ([PubMed](#)).



**Western Blotting**

**Image 1.** CYP2C9 Antibody (N-term)(Ascites) ABIN1882233 western blot analysis in NCI- cell line lysates (35 µg/lane). This demonstrates the CYP2C9 antibody detected the CYP2C9 protein (arrow).